PURPOSE: To explore different allometric equations for scaling clearance across the human life-span using propofol as a model drug. METHODS: Data from seven previously published propofol studies ((pre)term neonates, infants, toddlers, children, adolescents and adults) were analysed using NONMEM VI. To scale clearance, a bodyweight-based exponential equation with four different structures for the exponent was used: (I) 3/4 allometric scaling model; (II) mixture model; (III) bodyweight-cut-point separated model; (IV) bodyweight-dependent exponent model. RESULTS: Model I adequately described clearance in adults and older children, but overestimated clearance of neonates and underestimated clearance of infants. Use of two different exponents in Model II and Model III showed significantly improved performance, but yielded ambiguities on the boundaries of the two subpopulations. This discontinuity was overcome in Model IV, in which the exponent changed sigmoidally from 1.35 at a hypothetical bodyweight of 0 kg to a value of 0.56 from 10 kg onwards, thereby describing clearance of all individuals best. CONCLUSIONS: A model was developed for scaling clearance over the entire human life-span with a single continuous equation, in which the exponent of the bodyweight-based exponential equation varied with bodyweight.
PURPOSE: To explore different allometric equations for scaling clearance across the human life-span using propofol as a model drug. METHODS: Data from seven previously published propofol studies ((pre)term neonates, infants, toddlers, children, adolescents and adults) were analysed using NONMEM VI. To scale clearance, a bodyweight-based exponential equation with four different structures for the exponent was used: (I) 3/4 allometric scaling model; (II) mixture model; (III) bodyweight-cut-point separated model; (IV) bodyweight-dependent exponent model. RESULTS: Model I adequately described clearance in adults and older children, but overestimated clearance of neonates and underestimated clearance of infants. Use of two different exponents in Model II and Model III showed significantly improved performance, but yielded ambiguities on the boundaries of the two subpopulations. This discontinuity was overcome in Model IV, in which the exponent changed sigmoidally from 1.35 at a hypothetical bodyweight of 0 kg to a value of 0.56 from 10 kg onwards, thereby describing clearance of all individuals best. CONCLUSIONS: A model was developed for scaling clearance over the entire human life-span with a single continuous equation, in which the exponent of the bodyweight-based exponential equation varied with bodyweight.
Authors: T W Schnider; C F Minto; P L Gambus; C Andresen; D B Goodale; S L Shafer; E J Youngs Journal: Anesthesiology Date: 1998-05 Impact factor: 7.892
Authors: C A Knibbe; H J Voortman; L P Aarts; P F Kuks; R Lange; H J Langemeijer; M Danhof Journal: Br J Clin Pharmacol Date: 1999-06 Impact factor: 4.335
Authors: B K Kataria; S A Ved; H F Nicodemus; G R Hoy; D Lea; M Y Dubois; J W Mandema; S L Shafer Journal: Anesthesiology Date: 1994-01 Impact factor: 7.892
Authors: Joseph F Standing; Brian J Anderson; Stefanie Hennig; Nick H Holford; Trevor N Johnston; Catherijne A J Knibbe; Dagan O Lonsdale; Amin Rostami-Hodjegan Journal: Clin Pharmacokinet Date: 2018-11 Impact factor: 6.447
Authors: Cinzia Auriti; Marco Falcone; Maria Paola Ronchetti; Bianca Maria Goffredo; Sara Cairoli; Rosamaria Crisafulli; Fiammetta Piersigilli; Tiziana Corsetti; Andrea Dotta; Manjunath P Pai Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191